## OMCL: Omnicell, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 8.2% in mid entry zone (4.0-10.0%), top 7% cross-sectional ranking. Short-term MRS_5 (3.2%) confirms momentum alignment. Strong momentum (+7.8% 5-day acceleration). Outperforming sector by 10.5%. Caution: overbought RSI (72).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($37.49)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Omnicell (Nasdaq: OMCL) to host ASHP Midyear innovation update, investor Q&A**
- Source: Stock Titan | 20251203T110938 | Neutral | Relevance: 100%
- Omnicell, Inc. (Nasdaq: OMCL) announced it will host an Innovation Update and Investor Q&A Session at the ASHP Midyear Clinical Meeting & Exhibition in Las Vegas on Monday, December 8, 2025. The Innovation Update will be in-person only, while the Q&A session will be available in person and via webcast. Key Omnicell executives, including Chairman and CEO Randall Lipps, COO Nnamdi Njoku, and CFO Baird Radford, will be present.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 10 ($2.25M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 58.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 17.1% (-2.3%)
- Vanguard Group Inc: 12.5% (-0.4%)
- Dimensional Fund Adv: 5.3% (+9.1%)
- Cadian Capital Manag: 4.7% (+25.9%)
- State Street Corpora: 4.6% (-2.0%)

### Key Risks

1. Elevated short interest (8.9%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +7.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.28 elevated, pricing in significant growth expectations. Forward P/E 22.0x stretched relative to 8% growth. Insider selling cluster ($2.2M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.1B |
| Beta | 0.83 |
| 52W Range | $22.66 - $47.69 |
| Short Interest | 8.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.28 |
| Forward P/E | 22.0 |
| Current P/E | 23.7 |
| YoY Growth | 7.8% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 0.3% to 8.2% (+7.8% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 93rd percentile. MRS_5 at 3.2% confirms short-term momentum alignment. AM_20 at 10.6% shows strong absolute momentum above own 20MA. Outperforming sector by 10.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 72, risk of mean reversion. Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: +STN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 8.16% (CS: 93) | Strong |
| RSI_14 | 71.7 | Overbought |
| MACD Histogram | 0.36 | Bullish |
| vs SMA20 | 1.106x | Above |
| vs SMA50 | 1.215x | Above |
| vs SMA200 | 1.272x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $40.49
- **Stop Loss:** $37.49 (7.4% risk)
- **Target:** $44.99 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 166
- **Position Value:** $6,721.34
- **Portfolio %:** 6.72%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-05 (Est: $0.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.36 | $0.51 | +40.7% |
| 2025Q2 | $0.27 | $0.45 | +66.7% |
| 2025Q1 | $0.20 | $0.26 | +27.1% |
| 2024Q4 | $0.58 | $0.60 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*